Exelixis, Inc. (EXEL) announced promising data from the CABINET trial, a pivotal Phase 3 study assessing Cabozantinib against a placebo in two cohorts of patients with previously treated neuroendocrine tumors. The results revealed a notable improvement in progression-free survival compared to the placebo, encompassing key subgroups of patients with advanced neuroendocrine tumors.
The trial incorporated two patient cohorts: one with advanced pancreatic neuroendocrine tumors and another with advanced extra-pancreatic neuroendocrine tumors.
The findings from the Phase 3 Pivotal CABINET Study evaluating Cabozantinib will be presented at ESMO 2024 and published in the New England Journal of Medicine.
Jennifer Chan, the principal investigator of the CABINET trial, remarked, "These final results are encouraging, indicating that Cabozantinib offers a clinically significant treatment advantage for patients with previously treated advanced neuroendocrine tumors, including all major clinical subgroups. The data suggests that Cabozantinib could become a new standard of care for patients urgently in need of treatment alternatives."
The CABINET trial was a multicenter, randomized, double-blind, placebo-controlled phase 3 study, enrolling a total of 298 patients in the United States.
